(Q38071397)

28 August 2017

1 reference

title

The role of HBsAg quantification for monitoring natural history and treatment outcome (English)

1 reference

28 August 2017

4

Patrick Marcellin

1 reference

28 August 2017

author name string

Michelle Martinot-Peignoux

series ordinal

1

1 reference

28 August 2017

Martine Lapalus

series ordinal

2

1 reference

28 August 2017

Tarik Asselah

series ordinal

3

1 reference

28 August 2017

publication date

1 February 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

33 Suppl 1

1 reference

28 August 2017

page(s)

125-132

1 reference

Hepatitis B virus infection--natural history and clinical consequences

28 August 2017

cites work

1 reference

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

21 January 2018

1 reference

Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.

21 January 2018

1 reference

Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia

21 January 2018

1 reference

Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers

21 January 2018

1 reference

Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective.

21 January 2018

1 reference

Correlation between the Elecsys HBsAg II assay and the Architect assay for the quantification of hepatitis B surface antigen (HBsAg) in the serum.

21 January 2018

1 reference

A comparison of two assays for quantification of Hepatitis B surface Antigen in patients with chronic hepatitis B.

21 January 2018

1 reference

Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review

21 January 2018

1 reference

Hepatitis B surface antigen quantification: why and how to use it in 2011 - a core group report

21 January 2018

1 reference

Relationship of clinical and virological factors with hepatitis activity in hepatitis B e antigen-negative chronic hepatitis B virus-infected patients

21 January 2018

1 reference

Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers

21 January 2018

1 reference

Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?

21 January 2018

1 reference

Management of hepatitis B: 2000--summary of a workshop

21 January 2018

1 reference

Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers.

21 January 2018

1 reference

High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B.

21 January 2018

1 reference

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

21 January 2018

1 reference

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B.

21 January 2018

1 reference

Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B.

21 January 2018

1 reference

Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline

21 January 2018

1 reference

Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype

21 January 2018

1 reference

Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients

21 January 2018

1 reference

Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

21 January 2018

1 reference

Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels

21 January 2018

1 reference

Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a

21 January 2018

1 reference

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

21 January 2018

1 reference

High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study

21 January 2018

1 reference

New perspectives in the therapy of chronic hepatitis B.

21 January 2018

1 reference

Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C.

21 January 2018

1 reference

Correlation of serum hepatitis B surface antigen level with response to entecavir in naïve patients with chronic hepatitis B.

21 January 2018

1 reference

Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir.

21 January 2018

1 reference

Factors associated with serum hepatitis B surface antigen levels and its on-treatment changes in patients under lamivudine therapy.

21 January 2018

1 reference

Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients

21 January 2018

1 reference

Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients

21 January 2018

1 reference

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

21 January 2018

1 reference

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

21 January 2018

1 reference

On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients

21 January 2018

1 reference

High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load

21 January 2018

1 reference

Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients

21 January 2018

1 reference

Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-α2a

21 January 2018

1 reference

Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype

21 January 2018

1 reference

Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a

21 January 2018

1 reference

Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/LIV.12075

1 reference

28 August 2017

1 reference